Cargando…

Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort

OBJECTIVE: The Omicron BA.5.2 variant of SARS-CoV-2 has undergone several evolutionary adaptations, leading to multiple subvariants. Rapid and accurate characterization of these subvariants is essential for effective treatment, particularly in critically ill patients. This study leverages Next-Gener...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Jianliang, Xia, Mingkai, Liu, Rangjiao, Wang, Shaobo, Duan, Xinyi, Peng, Jiong, Li, Enping, Zhou, Yanping, Li, Chengyou, Zhang, Quan, Tian, Jixian, Wang, Xinjian, Su, Zhongrui, Tan, Jun, Peng, Bo, Zhang, Jianhui, Li, Jin, Dai, Lizhong, Lei, Mingsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642935/
https://www.ncbi.nlm.nih.gov/pubmed/37965255
http://dx.doi.org/10.3389/fcimb.2023.1288914
_version_ 1785147048671051776
author Huang, Jianliang
Xia, Mingkai
Liu, Rangjiao
Wang, Shaobo
Duan, Xinyi
Peng, Jiong
Li, Enping
Zhou, Yanping
Li, Chengyou
Zhang, Quan
Tian, Jixian
Wang, Xinjian
Su, Zhongrui
Tan, Jun
Peng, Bo
Zhang, Jianhui
Li, Jin
Dai, Lizhong
Lei, Mingsheng
author_facet Huang, Jianliang
Xia, Mingkai
Liu, Rangjiao
Wang, Shaobo
Duan, Xinyi
Peng, Jiong
Li, Enping
Zhou, Yanping
Li, Chengyou
Zhang, Quan
Tian, Jixian
Wang, Xinjian
Su, Zhongrui
Tan, Jun
Peng, Bo
Zhang, Jianhui
Li, Jin
Dai, Lizhong
Lei, Mingsheng
author_sort Huang, Jianliang
collection PubMed
description OBJECTIVE: The Omicron BA.5.2 variant of SARS-CoV-2 has undergone several evolutionary adaptations, leading to multiple subvariants. Rapid and accurate characterization of these subvariants is essential for effective treatment, particularly in critically ill patients. This study leverages Next-Generation Sequencing (NGS) to elucidate the clinical and immunological features across different Omicron BA.5.2 subvariants. METHODS: We enrolled 28 patients infected with the Omicron variant, hospitalized in Zhangjiajie People’s Hospital, Hunan, China, between January 20, 2023, and March 31, 2023. Throat swabs were collected upon admission for NGS-based identification of Omicron subvariants. Clinical data, including qSOFA scores and key laboratory tests, were collated. A detailed analysis of lymphocyte subsets was conducted to ascertain the extent of immune cell damage and disease severity. RESULTS: Patients were infected with various Omicron subvariants, including BA.5.2.48, BA.5.2.49, BA.5.2.6, BF.7.14, DY.1, DY.2, DY.3, and DY.4. Despite having 43 identical mutation sites, each subvariant exhibited unique marker mutations. Critically ill patients demonstrated significant depletion in total lymphocyte count, T cells, CD4, CD8, B cells, and NK cells (P < 0.05). However, there were no significant differences in clinical and immunological markers across the subvariants. CONCLUSION: This study reveals that critically ill patients infected with different Omicron BA.5.2 subvariants experience similar levels of cellular immune dysfunction and inflammatory response. Four mutations - ORF1a:K3353R, ORF1a:L3667F, ORF1b:S997P, S:T883I showed correlation with immunological responses although this conclusion suffers from the small sample size. Our findings underscore the utility of NGS in the comprehensive assessment of infectious diseases, contributing to more effective clinical decision-making.
format Online
Article
Text
id pubmed-10642935
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-106429352023-11-14 Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort Huang, Jianliang Xia, Mingkai Liu, Rangjiao Wang, Shaobo Duan, Xinyi Peng, Jiong Li, Enping Zhou, Yanping Li, Chengyou Zhang, Quan Tian, Jixian Wang, Xinjian Su, Zhongrui Tan, Jun Peng, Bo Zhang, Jianhui Li, Jin Dai, Lizhong Lei, Mingsheng Front Cell Infect Microbiol Cellular and Infection Microbiology OBJECTIVE: The Omicron BA.5.2 variant of SARS-CoV-2 has undergone several evolutionary adaptations, leading to multiple subvariants. Rapid and accurate characterization of these subvariants is essential for effective treatment, particularly in critically ill patients. This study leverages Next-Generation Sequencing (NGS) to elucidate the clinical and immunological features across different Omicron BA.5.2 subvariants. METHODS: We enrolled 28 patients infected with the Omicron variant, hospitalized in Zhangjiajie People’s Hospital, Hunan, China, between January 20, 2023, and March 31, 2023. Throat swabs were collected upon admission for NGS-based identification of Omicron subvariants. Clinical data, including qSOFA scores and key laboratory tests, were collated. A detailed analysis of lymphocyte subsets was conducted to ascertain the extent of immune cell damage and disease severity. RESULTS: Patients were infected with various Omicron subvariants, including BA.5.2.48, BA.5.2.49, BA.5.2.6, BF.7.14, DY.1, DY.2, DY.3, and DY.4. Despite having 43 identical mutation sites, each subvariant exhibited unique marker mutations. Critically ill patients demonstrated significant depletion in total lymphocyte count, T cells, CD4, CD8, B cells, and NK cells (P < 0.05). However, there were no significant differences in clinical and immunological markers across the subvariants. CONCLUSION: This study reveals that critically ill patients infected with different Omicron BA.5.2 subvariants experience similar levels of cellular immune dysfunction and inflammatory response. Four mutations - ORF1a:K3353R, ORF1a:L3667F, ORF1b:S997P, S:T883I showed correlation with immunological responses although this conclusion suffers from the small sample size. Our findings underscore the utility of NGS in the comprehensive assessment of infectious diseases, contributing to more effective clinical decision-making. Frontiers Media S.A. 2023-10-30 /pmc/articles/PMC10642935/ /pubmed/37965255 http://dx.doi.org/10.3389/fcimb.2023.1288914 Text en Copyright © 2023 Huang, Xia, Liu, Wang, Duan, Peng, Li, Zhou, Li, Zhang, Tian, Wang, Su, Tan, Peng, Zhang, Li, Dai and Lei https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Huang, Jianliang
Xia, Mingkai
Liu, Rangjiao
Wang, Shaobo
Duan, Xinyi
Peng, Jiong
Li, Enping
Zhou, Yanping
Li, Chengyou
Zhang, Quan
Tian, Jixian
Wang, Xinjian
Su, Zhongrui
Tan, Jun
Peng, Bo
Zhang, Jianhui
Li, Jin
Dai, Lizhong
Lei, Mingsheng
Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort
title Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort
title_full Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort
title_fullStr Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort
title_full_unstemmed Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort
title_short Comparative analysis of clinical and immunological profiles across Omicron BA.5.2 subvariants using next-generation sequencing in a Chinese cohort
title_sort comparative analysis of clinical and immunological profiles across omicron ba.5.2 subvariants using next-generation sequencing in a chinese cohort
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10642935/
https://www.ncbi.nlm.nih.gov/pubmed/37965255
http://dx.doi.org/10.3389/fcimb.2023.1288914
work_keys_str_mv AT huangjianliang comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT xiamingkai comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT liurangjiao comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT wangshaobo comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT duanxinyi comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT pengjiong comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT lienping comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT zhouyanping comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT lichengyou comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT zhangquan comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT tianjixian comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT wangxinjian comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT suzhongrui comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT tanjun comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT pengbo comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT zhangjianhui comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT lijin comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT dailizhong comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort
AT leimingsheng comparativeanalysisofclinicalandimmunologicalprofilesacrossomicronba52subvariantsusingnextgenerationsequencinginachinesecohort